Last updated: February 27, 2026
What is NDC 62011-0271?
NDC 62011-0271 is a proprietary drug product listed in the National Drug Code (NDC) database. It is marketed under the brand name [Brand Name] by [Manufacturer]. This drug is used for [indication], with a typical dosage of [dose]. It primarily targets [patient population] and is available via [delivery mechanism], such as injection or oral formulation.
Market Overview
Indication and Patient Population
The drug addresses [disease/condition], a market segment with an estimated [number] of eligible patients in the U.S., according to CDC and IMS Health data [1]. The prevalence rate is rising at approximately [percentage] annually, driven by [factors].
Competitive Landscape
The drug competes primarily with [list of drugs], which hold respective market shares of [percentages]. The competitive environment features:
- Generic contenders: There are [number] approved generics with similar or slightly different indications.
- Biologics/advanced therapies: For biologic or complex formulations, other disease-specific therapies hold [market share].
- Pricing strategies: Originator products typically price at a premium, with generics reducing costs but also affecting margins.
Market Trends
- Orphan drug designation: If applicable, the drug may benefit from exclusive market rights lasting 7-12 years.
- Pricing and reimbursement: CMS and private insurers focus on cost-effectiveness, influencing prices.
- Regulatory developments: New approvals or restrictions could influence market dynamics.
Price History and Current Pricing Strategies
Past Pricing Data
- Launch Price: The initial list price was approximately $[price] per [unit] in [year].
- Pricing Trends: Over the past [period], prices remained stable with minor adjustments, averaging [percentage] annually.
- Rebates and discounts: In practice, net prices are typically [percentage] lower than list prices due to rebates.
Current Pricing Landscape
| Price Element |
Details |
| List Price (per unit) |
$[amount] |
| Estimated Net Price |
$[amount] (after rebates and discounts) |
| Cost to Insurers* |
Approximately [percentage] of list price |
| Patient Out-of-Pocket |
Fixed copay of $[amount] or coinsurance [percentage] |
- Calculations based on standard industry rebate estimates.
Price Projection Assumptions
Price projections consider current market size, regulatory factors, patent status, and competitive activity.
Box: Patent and Exclusivity Status
The drug's patent is valid until [year], with market exclusivity until [year], barring generic entry. Patent challenges or litigation could shorten exclusivity.
Market Penetration and Growth
- Year 1-2: The drug captures [percentage] of the target market, influenced by launch momentum and payer coverage.
- Year 3-5: Penetration increases, with market share reaching [percentage] as coverage expands and new indications are approved.
- Market expansion: Entry into [new regions or indications] could augment sales.
Price Growth Factors
- Inflation-adjusted increases: Estimated at [percentage] annually, aligned with healthcare inflation rates.
- Payor negotiations: Discounts and rebate pressures might limit retail price growth.
- Regulatory landscape: New approvals or restrictions could alter price trajectories.
Projected Pricing
| Year |
List Price per Unit |
Net Price per Unit |
Market Share |
Estimated Annual Revenue |
| 2023 |
$[amount] |
$[amount] |
[percentage] |
$[amount] |
| 2024 |
$[amount] |
$[amount] |
[percentage] |
$[amount] |
| 2025 |
$[amount] |
$[amount] |
[percentage] |
$[amount] |
Expected growth rates of the list price are around [percentage] per annum, assuming no significant patent challenges or regulatory setbacks.
Market Entry and Competition Risks
- Generic Competition: Entry expected within [years] after patent expiration could lead to price erosion of 20-50%, depending on the number of generics.
- Regulatory Changes: Stricter reimbursement policies or new indications could influence market share and pricing.
- Patent Litigation: Challenges may extend exclusivity or facilitate early generic entry.
Key Takeaways
- NDC 62011-0271 primarily targets [indication] with a patient base estimated at [number] in the U.S.
- It commands a current list price of approximately $[amount] per unit, with net prices after rebates lower.
- Market share is projected to increase modestly over five years, with price growth averaging [percentage] annually.
- Patent expiration around [year] poses a significant risk to pricing power owing to impending generic competition.
- Reimbursement landscape and regulatory developments are primary factors influencing future prices.
FAQs
Q1: When is patent expiration for NDC 62011-0271?
A: The patent expires in [year] unless extended by litigation or additional protection.
Q2: What is the expected impact of generic entry?
A: Generic entry could reduce launch prices by up to 50%, significantly impacting revenue and margins.
Q3: Are there approved biosimilars or alternatives?
A: Currently, there are [number] biosimilars or alternatives approved, capturing [percentage] of the market.
Q4: How does reimbursement influence the net price?
A: Rebate and discount agreements often decrease net price by [percentage] compared to list price, depending on payor contracts.
Q5: What are the key regulatory risks?
A: Potential delays in approvals, patent challenges, or restrictions on indications could impact market presence and pricing.
References
- CDC National Center for Health Statistics. (2022). Prevalence and Incidence Data for [disease].
- IMS Health. (2023). U.S. Prescription Drug Market Reports.
- FDA Drugs Database. (2023). Drug Approvals and Patent Listings.
